GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (STU:NYZ) » Definitions » Current Deferred Revenue

Novacyt (STU:NYZ) Current Deferred Revenue : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Novacyt Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Novacyt's current deferred revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.

Novacyt Current Deferred Revenue Historical Data

The historical data trend for Novacyt's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Current Deferred Revenue Chart

Novacyt Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novacyt Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novacyt Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Novacyt's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Novacyt Business Description

Traded in Other Exchanges
Address
13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt Headlines

No Headlines